Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split of its common stock.
The reverse stock split is aimed at maintaining compliance with Nasdaq listing requirements.
The company's common stock is expected to begin trading on a split-adjusted basis on August 18, 2025.
Reverse Stock Split
1 for 3 reverse stock split to regain compliance with Nasdaq listing requirements.
Impact on Outstanding Shares
Reduction of outstanding common stock from about 4.77 million to approximately 1.59 million shares.
Shareholder Compensation
No fractional shares to be issued; shareholders entitled to cash in lieu of fractional shares.
CEO Statement
Interim CEO, Richard Paolone, emphasized the importance of the Nasdaq listing for shareholder value enhancement.
- The reverse stock split will consolidate every 3 shares into 1 share, reducing the total outstanding shares significantly.
- Entero Therapeutics aims to enhance shareholder value and maintain visibility with the Nasdaq listing through this strategic move.
Entero Therapeutics' strategic decision to implement a reverse stock split demonstrates their commitment to regulatory compliance and shareholder interests. The move reflects the company's efforts to strengthen its position in the market.